Send your comments and tips to whitecoat@globe.com
  Awards Beth Israel Deaconess Medical Ctr. Boston Medical Center Boston University Brigham and Women's Hospital Broad Institute Cambridge Health Alliance Caritas St. Elizabeth's Medical Ctr. Children's Hospital Boston Dana-Farber Cancer Institute Grants Harvard University Joslin Diabetes Center Lahey Clinic Mass. General Hospital Mass. Health Law McLean Hospital MIT New England Baptist Hospital Personnel Moves Public Health Research Short White Coat Tufts-New England Medical Center Tufts University UMass Memorial Medical Center University of Massachusetts VA Medical Centers    A Healthy Blog Running A Hospital Nature Network Boston SciBos - Corie Lok's blog Kevin, M.D. Blog, MD Nurse at small Dr. Gwenn Is In Healthy Children blog WBUR's CommonHealth Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram &
Gazette.
Boston Globe Health and Science staff:
Scott Allen Alice Dembner Carey Goldberg Liz Kowalczyk Stephen Smith Colin Nickerson Beth Daley Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor. Short White Coat blogger Ishani Ganguli Short White Coat blogger Jennifer Srygley  Week of:
November 11
Week of:
November 4
Week of:
October 28
Week of:
October 21
Week of:
October 14
Week of:
October 7
|
« Beth Israel Deaconess names research operations head | Main | Coming Sunday: A trusted doctor's sex change tests his patients » Friday, August 10, 2007Today's Globe: shots in abortions, Myozyme doses, Alnylam-US pact, heartburn drugsIn response to the Supreme Court decision upholding the Partial-Birth Abortion Ban Act, many abortion providers in Boston and around the country have adopted a defensive tactic. To avoid any chance of partially delivering a live fetus, they are injecting fetuses with lethal drugs before procedures. Genzyme Corp. is asking adult US patients with Pompe disease to skip two doses of its drug Myozyme in coming months so the Cambridge company can stretch supplies until regulators allow the treatment to be distributed from a new manufacturing plant. Alnylam Pharmaceuticals Inc. of Cambridge said yesterday that it has been awarded a $38.6 million government contract to develop RNAi therapeutics for biological threats. The popular heartburn drugs Prilosec and Nexium don't appear to spur heart problems, according to preliminary results of US and Canadian probes disclosed yesterday. Posted by Elizabeth Cooney at 06:39 AM
|
